1887

Abstract

We determined L1 antibodies for human papillomavirus (HPV) types 6, 11, 16, 18 and 45 by multiplex serology in our prospective HPV family study. We report seroprevalence, seroconversion and antibody decay in 290 women (mean age, 25.5 years) sampled before delivery and at 12, 24 and 36 months of follow-up. Multiplex HPV genotyping of the baseline oral and genital scrapings was performed. At baseline, seroprevalence of HPV 6, 11, 16, 18 and 45 was 53.3, 21.5, 34.9, 21.5 and 9.0 %, respectively. Seropositivity for low-risk HPV (LR-HPV) was associated significantly with age at onset of sexual activity (=0.001), number of sexual partners until age 20 (=0.018), lifetime number of sexual partners (=0.0001), history of genital warts (=0.0001) and being seropositive for high-risk (HR) HPV (=0.0001). The same covariates also predicted seropositivity for HR-HPV. During follow-up, 26.7, 13.9, 17.0, 16.8 and 6.6 % of the women seroconverted to L1 antigen of HPV 6, 11, 16, 18 and 45, respectively, between 18.2 and 23.8 months. Independent predictors of seroconversion to LR-HPV were unemployment (=0.019) and absence of anal sex practice (=0.031), and to HR-HPV, absence of smoking history and lifetime number of sexual partners. Decay of HPV 6, 11, 16, 18 and 45 antibodies was observed in 2.3, 4.0, 5.3, 4.5 and 1.5 % of the women, respectively, with decay time varying from 27.2 to 35.8 months. These data imply that (i) a substantial proportion of young women are seropositive for both LR- and HR-HPV types, (ii) they frequently undergo seroconversion within 18–24 months, predicted by common covariates, and (iii) antibody decay over 3 years is rare.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.007823-0
2009-06-01
2019-11-22
Loading full text...

Full text loading...

/deliver/fulltext/jgv/90/6/1515.html?itemId=/content/journal/jgv/10.1099/vir.0.007823-0&mimeType=html&fmt=ahah

References

  1. af Geijersstam, V., Kibur, M., Wang, Z., Koskela, P., Pukkala, E., Schiller, J., Lehtinen, M. & Dillner, J. ( 1998; ). Stability over time of serum antibody levels to human papillomavirus type 16. J Infect Dis 177, 1710–1714.[CrossRef]
    [Google Scholar]
  2. Anttila, M., Syrjänen, S., Ji, H., Saarikoski, S. & Syrjänen, K. ( 1999; ). Failure to demonstrate human papillomavirus DNA in epithelial ovarian cancer by general primer PCR. Gynecol Oncol 72, 337–341.[CrossRef]
    [Google Scholar]
  3. Carter, J. J., Koutsky, L. A., Wipf, G. C., Christensen, N. D., Lee, S. K., Kuypers, J., Kiviat, N. & Galloway, D. A. ( 1996; ). The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women. J Infect Dis 174, 927–936.[CrossRef]
    [Google Scholar]
  4. Carter, J. J., Koutsky, L. A., Hughes, J. P., Lee, S. K., Kuypers, J., Kiviat, N. & Galloway, D. A. ( 2000; ). Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis 181, 1911–1919.[CrossRef]
    [Google Scholar]
  5. Castle, P. E., Wacholder, S., Lorincz, A. T., Scott, D. R., Sherman, M. E., Glass, A. G., Rush, B. B., Schussler, J. E. & Schiffman, M. ( 2002; ). A prospective study of high-grade cervical neoplasia risk among human papillomavirus-infected women. J Natl Cancer Inst 94, 1406–1414.[CrossRef]
    [Google Scholar]
  6. Clifford, G. M., Shin, H. R., Oh, J. K., Waterboer, T., Ju, Y. H., Vaccarella, S., Quint, W., Pawlita, M. & Franceschi, S. ( 2007; ). Serologic response to oncogenic human papillomavirus types in male and female university students in Susan, South Korea. Cancer Epidemiol Biomarkers Prev 16, 1874–1879.[CrossRef]
    [Google Scholar]
  7. Diggle, P. J., Heagerty, P., Liang, K.-Y. & Zeger, S. L. ( 2002; ). In Analysis of Longitudinal Data, chapters 3–4, pp. 33–70. Oxford: Oxford University Press.
  8. Franco, E. L., Villa, L. L., Sobrinho, J. P., Prado, J. M., Rousseau, M. C., Désy, M. & Rohan, T. E. ( 1999; ). Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis 180, 1415–1423.[CrossRef]
    [Google Scholar]
  9. Hagensee, M. E., Slavinsky, J., III, Gaffga, C. M., Suros, J., Kissinger, P. & Martin, D. H. ( 1999; ). Seroprevalence of human papillomavirus type 16 in pregnant women. Obstet Gynecol 94, 653–658.[CrossRef]
    [Google Scholar]
  10. Hagensee, M. E., Koutsky, L. A., Lee, S. K., Grubert, T., Kuypers, J., Kiviat, N. B. & Galloway, D. A. ( 2000; ). Detection of cervical antibodies to human papillomavirus type 16 (HPV-16) capsid antigens in relation to detection of HPV-16 DNA and cervical lesions. J Infect Dis 181, 1234–1239.[CrossRef]
    [Google Scholar]
  11. Hardin, J. & Hilbe, J. M. ( 2003; ). In Generalized Estimating Equations, chapter 3, pp. 55–134. Boca Raton, FL: Chapman & Hall.
  12. Ho, G. Y., Bierman, R., Beardsley, L., Chang, C. J. & Burk, R. D. ( 1998; ). Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 338, 423–428.[CrossRef]
    [Google Scholar]
  13. Ho, G. Y., Studentsov, Y. Y., Bierman, R. & Burk, R. D. ( 2004; ). Natural history of human papillomavirus type 16 virus-like particle antibodies in young women. Cancer Epidemiol Biomarkers Prev 13, 110–116.[CrossRef]
    [Google Scholar]
  14. Jit, M., Vyse, A., Borrow, R., Pebody, R., Soldan, K. & Miller, E. ( 2007; ). Prevalence of human papillomavirus antibodies in young female subjects in England. Br J Cancer 97, 989–991.
    [Google Scholar]
  15. Kirnbauer, R., Hubbert, N. L., Wheeler, C. M., Becker, T. M., Lowy, D. R. & Schiller, J. T. ( 1994; ). A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16. J Natl Cancer Inst 86, 494–499.[CrossRef]
    [Google Scholar]
  16. Kjaer, S. K., van den Brule, A. J., Pauli, G., Svare, E. I., Sherman, M. E., Thomsen, B. L., Suntum, M., Bock, J. E., Poli, P. A. & other authors ( 2002; ). Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study. BMJ 325, 572 [CrossRef]
    [Google Scholar]
  17. Kulmala, S. M., Shabalova, I. P., Petrovitchev, N., Syrjänen, K. J., Gyllensten, U. B., Johansson, B. C. & Syrjänen, S. M., & the New Independent States of the former Soviet Union Cohort Study ( 2007; ). Type-specific persistence of high-risk human papillomavirus infections in the New Independent States of the former Soviet Union Cohort Study. Cancer Epidemiol Biomarkers Prev 16, 17–22.[CrossRef]
    [Google Scholar]
  18. Lehtinen, M., Kaasila, M., Pasanen, K., Patama, T., Palmroth, J., Laukkanen, P., Pukkala, E. & Koskela, P. ( 2006; ). Seroprevalence atlas of infections with oncogenic and non-oncogenic human papillomaviruses in Finland in the 1980s and 1990s. Int J Cancer 119, 2612–2619.[CrossRef]
    [Google Scholar]
  19. Marais, D. J., Sampson, C. C., Urban, M. I., Sitas, F. & Wiliamson, A. L. ( 2007; ). The seroprevalence of IgG antibodies to human papillomavirus (HPV) types HPV-16, HPV-18, and HPV-11 capsid-antigens in mothers and their children. J Med Virol 79, 1370–1374.[CrossRef]
    [Google Scholar]
  20. Manos, M. M., Ting, Y., Wright, D. K., Lewis, A. J., Broker, T. R. & Wolinsky, S. M. ( 1989; ). The use of polymerase chain reaction amplification for the detection of genital human papillomaviruses. Cancer Cells 7, 209–214.
    [Google Scholar]
  21. Michael, K. M., Waterboer, T., Sehr, P., Rother, A., Reidel, U., Boeing, H., Bravo, I. G., Schlehofer, J., Gärtner, B. C. & Pawlita, M. ( 2008; ). Seroprevalence of 34 human papillomavirus types in the German general population. PLoS Pathog 4, e1000091 [CrossRef]
    [Google Scholar]
  22. Miller, S. A., Dykes, D. D. & Polesky, H. F. ( 1988; ). A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16, 1215 [CrossRef]
    [Google Scholar]
  23. Molano, M., Van den Brule, A., Plummer, M., Weiderpass, E., Posso, H., Arslan, A., Meijer, C. J., Muñoz, N., Franceschi, S. & other authors ( 2003; ). Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology: a populationbased, 5-year follow-up study. Am J Epidemiol 158, 486–494.[CrossRef]
    [Google Scholar]
  24. Muñoz, N., Méndez, F, Posso, H, Molano, M, van der Brule, A. J., Ronderos, M, Meijer, C & Muñoz, A. for the Instituto Nacional de Cancerología HPV study group ( 2004; ). Incidence, duration, and determinants of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological results. J Infect Dis 190, 2077–2087.[CrossRef]
    [Google Scholar]
  25. Nikula, M., Koponen, P., Haavio-Mannila, E. & Hemminki, E. ( 2007; ). Sexual health among young adults in Finland: assessing risk and protective behaviour through a general health survey. Scand J Public Health 35, 298–305.[CrossRef]
    [Google Scholar]
  26. Olsen, A. O., Dillner, J., Gjøen, K. & Magnus, P. ( 1997; ). Seropositivity against HPV 16 capsids: a better marker of past sexual behaviour than presence of HPV DNA. Genitourin Med 73, 131–135.
    [Google Scholar]
  27. Rama, C. H., Roteli-Martins, C. M., Derchain, S. F., Oliveira, E. Z., Aldrighi, J. M. & Mariani Neto, C. ( 2006; ). Serological detection of anti HPV 16/18 and its association with pap smear in adolescents and young women. Rev Assoc Med Bras 52, 43–47.[CrossRef]
    [Google Scholar]
  28. Richardson, H., Kelsall, G., Tellier, P., Voyer, H., Abrahamowicz, M., Ferenczy, A., Couthée, F. & Franco, E. L. ( 2003; ). The natural history of type-specific human papillomavirus infections in female university students. Cancer Epidemiol Biomarkers Prev 12, 485–490.
    [Google Scholar]
  29. Rintala, M. A., Grenman, S. E., Jarvenkyla, M. E., Syrjanen, K. J. & Syrjanen, S. M. ( 2005a; ). High-risk types of human papillomavirus (HPV) DNA in oral and genital mucosa of infants during their first 3 years of life: experience from the Finnish HPV Family Study. Clin Infect Dis 41, 1728–1733.[CrossRef]
    [Google Scholar]
  30. Rintala, M. A., Grenman, S. E., Puranen, M. H., Isolauri, E., Ekblad, U., Kero, P. O. & Syrjänen, S. M. ( 2005b; ). Transmission of high-risk human papillomavirus (HPV) between parents and infant: a prospective study of HPV in families in Finland. J Clin Microbiol 43, 376–381.[CrossRef]
    [Google Scholar]
  31. Rintala, M., Grenman, S., Puranen, M. & Syrjanen, S. ( 2006; ). Natural history of oral papillomavirus infections in spouses: a prospective Finnish HPV Family Study. J Clin Virol 35, 89–94.[CrossRef]
    [Google Scholar]
  32. Rousseau, M. C., Pereira, J. S., Prado, J. C., Villa, L. L., Rohan, T. E. & Franco, E. L. ( 2001; ). Cervical coinfection with human papillomavirus (HPV) types as a predictor of acquisition and persistence of HPV infection. J Infect Dis 184, 1508–1517.[CrossRef]
    [Google Scholar]
  33. Schmitt, M., Bravo, I. G., Snijders, P. J., Gissmann, L., Pawlita, M. & Waterboer, T. ( 2006; ). Bead-based multiplex genotyping of human papillomaviruses. J Clin Microbiol 44, 504–512.[CrossRef]
    [Google Scholar]
  34. Silins, I., Kallings, I. & Dillner, J. ( 2000; ). Correlates of the spread of human papillomavirus infection. Cancer Epidemiol Biomarkers Prev 9, 953–959.
    [Google Scholar]
  35. Skjeldestad, F. E., Mehta, V., Sings, H. L., Øvreness, T., Turpin, J., Su, L., Boerckel, P., Roberts, C., Bryan, J. & other authors ( 2008; ). Seroprevalence and genital DNA prevalence of HPV types 6, 11, 16 and 18 in a cohort of young Norwegian women: study design and cohort characteristics. Acta Obstet Gynecol Scand 87, 81–88.[CrossRef]
    [Google Scholar]
  36. Snijders, P. J. F., van den Brule, A. J. C., Schrijnemakers, H. F. J., Snow, G., Meijer, C. J. L. M. & Walboomers, J. M. M. ( 1990; ). The use of general primers in the polymerase chain reaction permits the detection of a broad spectrum of human papillomavirus genotypes. J Gen Virol 71, 173–181.[CrossRef]
    [Google Scholar]
  37. Stone, K. M., Karem, K. L., Sternberg, M. R., McQuillan, G. M., Poon, A. D., Unger, E. R. & Reeves, W. C. ( 2002; ). Seroprevalence of human papillomavirus type 16 infection in the United States. J Infect Dis 186, 1396–1402.[CrossRef]
    [Google Scholar]
  38. Syrjänen, K., Yliskoski, M., Kataja, V., Hippeläinen, M., Syrjänen, S., Saarikoski, S. & Ryhänen, A. ( 1990; ). Prevalence of genital human papillomavirus infections in a mass-screened Finnish female population aged 20–65 years. Int J STD AIDS 1, 410–415.
    [Google Scholar]
  39. Syrjänen, S., Shabalova, I., Petrovichev, N., Podistov, J., Ivanchenko, O., Zakharenko, S., Nerovjna, R., Kljukina, L., Branovskaja, M. & other authors ( 2005a; ). Age-specific incidence and clearance of high-risk human papillomavirus infections in women in the former Soviet Union. Int J STD AIDS 16, 217–223.[CrossRef]
    [Google Scholar]
  40. Syrjänen, S., Shabalova, I. P., Petrovichev, N., Kozachenko, V. P., Zakharova, A., Pajanidi, A., Podistov, J. I., Chemeris, G., Soazeva, L. G. & other authors ( 2005b; ). Clearance of high-risk human papillomavirus (HPV) DNA and PAP smear abnormalities in a cohort of women subjected to HPV screening in the New Independent States (NIS) of the Former Soviet Union. Eur J Obstet Gynecol Reprod Biol 119, 219–227.[CrossRef]
    [Google Scholar]
  41. Thompson, D. L., Douglas, J. M., Jr, Foster, M., Hagensee, M. E., Diguiseppi, C., Barón, A. E., Cameron, J. E., Spencer, T. C., Zenilman, J. & other authors ( 2004; ). Seroepidemiology of infection with human papillomavirus 16, in men and women attending sexually transmitted disease clinics in the United States. J Infect Dis 190, 1563–1574.[CrossRef]
    [Google Scholar]
  42. van Doornum, G., Prins, M., Andersson-Ellström, A. & Dillner, J. ( 1998; ). Immunoglobulin A, G, and M responses to L1 and L2 capsids of human papillomavirus types 6, 11, 16, 18, and 33 L1 after newly acquired infection. Sex Transm Infect 74, 354–360.[CrossRef]
    [Google Scholar]
  43. Villa, L. L., Ault, K. A., Giuliano, A. R., Costa, R. L., Petta, C. A., Andrade, R. P., Brown, D. R., Ferenczy, A., Harper, D. M. & other authors ( 2006; ). Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16, and 18. Vaccine 24, 5571–5583.[CrossRef]
    [Google Scholar]
  44. Viscidi, R. P., Kotloff, K. L., Clayman, B., Russ, K., Shapiro, S. & Shah, K. V. ( 1997; ). Prevalence of antibodies to human papillomavirus (HPV) type 16 virus-like particles in relation to cervical HPV infection among college women. Clin Diagn Lab Immunol 4, 122–126.
    [Google Scholar]
  45. Viscidi, R. P., Snyder, B., Cu-Uvin, S., Hogan, J. W., Clayman, B., Klein, R. S., Sobel, J. & Shah, K. V. ( 2005; ). Human papillomavirus capsid antibody response to natural infection and risk of subsequent HPV infection in HIV-positive and HIV-negative women. Cancer Epidemiol Biomarkers Prev 14, 283–288.
    [Google Scholar]
  46. Wang, S. S., Schiffman, M., Shields, T. S., Herrero, R., Hildesheim, A., Bratti, M. C., Sherman, M. E., Rodriguez, A. C., Castle, P. E. & other authors ( 2003; ). Seroprevalence of human papillomavirus-16, -18, -31, and -45 in a population-based cohort of 10000 women in Costa Rica. Br J Cancer 89, 1248–1254.[CrossRef]
    [Google Scholar]
  47. Wang, S. S., Schiffman, M., Herrero, R., Carreon, J., Hildesheim, A., Rodriguez, A. C., Bratti, M. C., Sherman, M. E., Morales, J. & other authors ( 2004; ). Determinants of human papillomavirus 16 serological conversion and persistence in a population-based cohort of 10 000 women in Costa Rica. Br J Cancer 91, 1269–1274.[CrossRef]
    [Google Scholar]
  48. Wang, I. J., Viscidi, R., Hwang, K. C., Lin, T. Y., Chen, C. J., Huang, L. M., Chen, H. H. & Chen, C. J. ( 2008; ). Seroprevalence and risk factors for human papillomavirus in Taiwan. J Trop Pediatr 54, 14–18.
    [Google Scholar]
  49. Waterboer, T., Sehr, P., Michael, K. M., Franceschi, S., Nieland, J. D., Joos, T. O., Templin, M. F. & Pawlita, M. ( 2005; ). Multiplex human papillomavirus serology based on in situ-purified glutathione S-transferase fusion proteins. Clin Chem 51, 1845–1853.[CrossRef]
    [Google Scholar]
  50. Waterboer, T., Sehr, P. & Pawlita, M. ( 2006; ). Suppression of non-specific binding in serological Luminex assays. J Immunol Methods 309, 200–204.[CrossRef]
    [Google Scholar]
  51. Wideroff, L., Schiffman, M. H., Hoover, R., Tarone, R. E., Nonnenmacher, B., Hubbert, N., Kirnbauer, R., Greer, C. E., Lorincz, A. T. & other authors ( 1996; ). Epidemiologic determinants of seroreactivity to human papillomavirus (HPV) type 16 virus-like particles in cervical HPV-16 DNA-positive and-negative women. J Infect Dis 174, 937–943.[CrossRef]
    [Google Scholar]
  52. Woodman, C. B., Collins, S., Winter, H., Bailey, A., Ellis, J., Prior, P., Yates, M., Rollason, T. P. & Young, L. S. ( 2001; ). Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet 357, 1831–1836.[CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.007823-0
Loading
/content/journal/jgv/10.1099/vir.0.007823-0
Loading

Data & Media loading...

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error